OpenBiome engages with media at the local, national, and international level. Our goal is to educate without hyping; to share our excitement around microbiome research with careful consideration of the scientific evidence.
Read our press releases to learn about the latest developments at OpenBiome! From welcoming new members to our team, our findings at conferences, and marking milestones in patient care, we are excited to share our progress with you.
OpenBiome screens for antibiotic-resistant bacteria, including the bacteria involved in a recent safety alert from FDA. OpenBiome did not provide the FMT material linked to this event and our service remains uninterrupted.
On October 3, 2018, the week of our fifth anniversary, we processed and shipped our 40,000th FMT preparation. In partnership with stool donors and healthcare professionals across the country, these treatments have traveled to a network of more than 1,100 hospitals and clinics that have reshaped medical care for patients with recurrent C. difficile.
The pilot, open-label study is funded by Gates Foundation, Child Relief International and the Thrasher Research Fund.
SOMERVILLE, Mass. – This month, OpenBiome celebrated two notable milestones in its effort to expand safe access to fecal microbiota transplantation (FMT):
- OpenBiome partnered with its 1,000th clinical provider.
- OpenBiome shipped out its 30,000th treatment.
OpenBiome is pleased to announce a collaboration with the American Gastroenterological Association (AGA) on the Fecal Microbiota Transplantation (FMT) National Registry, planned to be the largest observational FMT study in history.
READ MORE NEWS FROM OPENBIOME HERE.